Device Trial Radar · NCT04912323
Study of the R3 Vascular Drug-Eluting Bioresorbable Scaffold in Treating Below the Knee Arterial Disease
Last checked: Nov 20, 2026Latest source record: Apr 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Aug 17, 2021
Primary completion
Dec 31, 2026
Study completion Dec 31, 2031
Sponsor
- Lead sponsor
- R3 Vascular Inc.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- Massachusetts General Physicians Organization / Vascore; Cardiovascular Research Foundation, New York
- First posted
- Jun 3, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This first-in-human clinical feasibility study will evaluate the safety and performance of the R3 Vascular MAGNITUDE® Bioresorbable Drug-Eluting Scaffold and Delivery System in patients undergoing treatment for peripheral arterial disease severe enough to have significantly reduced the blood supply to their leg. The severe reduction in blood flow causes lifestyle limiting leg pain for these patients, and may lead to amputation of the affected limb due to the loss of tissue in the leg or foot from ulcers or gangrene. The investigational device being studied in this trial is intended to restore blood flow to the affected limb, providing symptomatic relief to the patient and reducing the risk of limb amputation. The scaffold is a type of vascular stent placed within the diseased artery below the knee to improve blood flow. Unlike commercially available metallic stents which are permanently placed within the artery, the MAGNITUDE® Bioresorbable scaffold is made of a polymer material that will completely dissolve away over time, providing the support necessary to the artery while it is healing after the treatment procedure and then slowly disappearing from the artery once that support is no longer needed. The investigational scaffold has been successfully used to treat vascular blockages in the coronary arteries of the heart, but the RESOLV I study will be the first time this device has been used to improve blood flow in the arteries of the lower leg. Patients enrolled in this study may have up to three vascular blockages in their lower leg arteries treated with the MAGNITUDE® Bioresorbable scaffold, and then will be assessed over the course of the following five years to evaluate whether the investigational treatment was successful in safely alleviating their leg pain and other symptoms.
Conditions
- Peripheral Arterial Disease
- Atherosclerotic Lesion
- Lower Extremity Ischemia
- Lower Extremity Claudication
Interventions
Percutaneous Implantation of the MAGNITUDE® Bioresorbable Arterial ScaffoldDevice
Placement of one or more MAGNITUDE® bioresorbable scaffolds using a percutaneous technique at one or more arterial stenoses.
Primary outcomes
What the sponsor says the trial is designed to measure.
- (Safety) Freedom from MALE and PODTime frame: MALE is assessed at 180 days and POD is assessed at 30 days (post implantation procedure)
- (Performance) Primary Patency of the Target Lesion(s)Time frame: Assessed at 180 days (post implantation procedure)
Locations
7 sites in 3 countries. Site status is shown where the registry gives one.
Medical University Graz
Graz, Austria · Recruiting
CRCHUM Université Montreal
Montreal, Canada · Recruiting
Hopital Saint-Francois d'Assise
Québec, Canada · Active not recruiting
4 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.